SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : CEPH
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: WeirdPro Randy who wrote (210)5/9/1997 6:28:00 AM
From: harkenman   of 998
 
About 30,000 people are estimated to be afflicted with the disease (ALS) in the U.S. In recent years, several biotechnology
companies have suffered high-profile failures in their
attempts to use nerve-growth factors such as Myotrophin
to treat the disease. But a different type of drug,
Rhone-Poulenc Rorer Inc.'s Rilutek, won FDA approval in
1995 to treat the malady.

source:
update.wsj.com

You may have been there but the FDA will listen to the panel, not your post. They (FDA) also will review the data. Panels are usually more lenient than the FDA. A t-IND is already approved therefore no rush to approve dud, oops I mean drug.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News